Scynexis (SCYX) Other Non-Current Liabilities (2013 - 2026)
Scynexis' (SCYX) quarterly Other Non-Current Liabilities came in at $800000.0 in Q2 2026, down 72.45% on a YoY basis from $2.9 million in Q2 2025, and down 95.77% quarter-over-quarter from $18.9 million in Q1 2026.
Analysis
Scynexis (SCYX) Other Non-Current Liabilities (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Other Non-Current Liabilities for 13 consecutive years, with $800000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Other Non-Current Liabilities fell 72.45% year-over-year to $800000.0; the trailing twelve-month figure through Jun 2026 stood at $800000.0 (down 72.45% YoY), and the FY2025 full-year result was $2.2 million, down 72.19% from the prior year.
- Other Non-Current Liabilities eased to $800000.0 in Q2 2026 per SCYX's latest filing, from $18.9 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $40.3 million in Q1 2023 and bottomed at $800000.0 in Q2 2026.
- Historically, Other Non-Current Liabilities has averaged $15.4 million across 5 years, with a median of $15.1 million in 2024.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities slumped 83.97% in 2022, then jumped 403.96% in 2023.
- Over 5 years, Other Non-Current Liabilities stood at $18.6 million in 2022, then rose by 16.93% to $21.8 million in 2023, then plunged by 63.3% to $8.0 million in 2024, then tumbled by 72.19% to $2.2 million in 2025, then sank by 64.04% to $800000.0 in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $800000.0, $18.9 million, and $2.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 800,000.00 |
| Mar 31, 2026 | 18.90 Mn |
| Dec 31, 2025 | 2.23 Mn |
| Sep 30, 2025 | 3.54 Mn |
| Jun 30, 2025 | 2.90 Mn |
| Mar 31, 2025 | 5.10 Mn |
| Dec 31, 2024 | 8.00 Mn |
| Sep 30, 2024 | 11.21 Mn |
| Jun 30, 2024 | 18.00 Mn |
| Mar 31, 2024 | 12.20 Mn |
| Dec 31, 2023 | 21.80 Mn |
| Sep 30, 2023 | 24.60 Mn |
| Jun 30, 2023 | 32.10 Mn |
| Mar 31, 2023 | 40.32 Mn |
| Dec 31, 2022 | 18.64 Mn |
| Sep 30, 2022 | 27.73 Mn |
| Jun 30, 2022 | 21.23 Mn |
| Mar 31, 2022 | 8.00 Mn |
| Dec 31, 2021 | 18.06 Mn |
| Sep 30, 2021 | 15.30 Mn |